AB
VRDN icon

Amalgamated Bank’s Viridian Therapeutics VRDN Stock Holding History

Amalgamated Bank’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,510
Closed -$78K – 2784
2025
Q4 		$78K Sell
2,510
-21
-0.8% -$576 ﹤0.01% 1736
2025
Q3 		$55K Hold
2,531
– – ﹤0.01% 1818
2025
Q2 		$35K Hold
2,531
– – ﹤0.01% 1931
2025
Q1 		$34K Buy
2,531
+840
+50% +$14.3K ﹤0.01% 1898
2024
Q4 		$32K Hold
1,691
– – ﹤0.01% 1965
2024
Q3 		$38K Hold
1,691
– – ﹤0.01% 1928
2024
Q2 		$22K Hold
1,691
– – ﹤0.01% 2088
2024
Q1 		$30K Sell
1,691
-3,738
-69% -$72.5K ﹤0.01% 2010
2023
Q4 		$118K Sell
5,429
-406
-7% -$6.41K ﹤0.01% 1950
2023
Q3 		$90K Hold
5,835
– – ﹤0.01% 2039
2023
Q2 		$139K Buy
5,835
+824
+16% +$21.1K ﹤0.01% 1959
2023
Q1 		$127K Sell
5,011
-863
-15% -$27.7K ﹤0.01% 1957
2022
Q4 		$172K Buy
5,874
+1,907
+48% +$43.9K ﹤0.01% 1919
2022
Q3 		$81K Buy
3,967
+107
+3% +$1.92K ﹤0.01% 2251
2022
Q2 		$45K Buy
+3,860
New +$51.9K ﹤0.01% 2547

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Amalgamated Bank's VRDN Position: Q1 2026 in Review

Amalgamated Bank sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 2,510 shares — an estimated $78K sold.

Amalgamated Bank first reported a position in VRDN in Q2 2022 and held it in 15 quarters. The position peaked at $172K in Q4 2022. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Amalgamated Bank reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 2,510 Viridian Therapeutics shares in Q1 2026, an estimated $78K.
  • Amalgamated Bank first reported a position in Viridian Therapeutics in Q2 2022 and held it in 15 quarters.
  • Amalgamated Bank's Viridian Therapeutics position peaked at $172K in Q4 2022.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.